Vogenx, Inc.
Healthcare / Biotechnology
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Performance
--
Today 0.00 (0.00%)
VOGX
Metrics
Market Cap219M
Latest Price$33.39
Previous Close$32.21
Volume31K
52 Week High$16.65
52 Week Low$12.95
52 Week Change21.15%
Average Volume209K
Revenue0
EPS-0.2
P/E Ratio0
Forward P/E0
Price/Book-59.211
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Dividend Yield0.00%